Vasoactive intestinal peptide (VIP) research, identity and evidence limits
VIP is a signaling peptide studied as a biomarker and experimental intervention. A change in natural VIP levels does not demonstrate that administering VIP treats the associated condition.
Identity and formulation
The abbreviation VIP denotes vasoactive intestinal peptide or polypeptide. In a paper it may be a measured endogenous hormone, an injected experimental material or one element of a pathway.
Identify which role VIP has before treating a reference as evidence for supplementation. A study indexed with VIP is not necessarily a study administering it.
What the studies show
Several source-page references concern VIP measurements rather than treatment. The directly reviewed human papers assess disease activity or associations with symptoms. A lamb experiment does administer VIP, but its diet, species and endpoints differ substantially from human gastrointestinal or neurological claims.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease.
Observational measurements in 115 adults with inflammatory bowel disease Reading scope: PubMed bibliographic record and abstract |
Circulating VIP levels were associated with clinical disease activity. | No VIP treatment was tested; the association cannot establish that raising or lowering VIP would help patients. |
| Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females.
Study of 37 healthy women with symptom, imaging and plasma measurements Reading scope: PubMed bibliographic record and abstract |
VIP concentrations were associated with selected affective symptoms and brain measures. | Associations are not randomized intervention effects or evidence of treating anxiety or depression. |
| The impact of exogenous vasoactive intestinal polypeptide on inflammatory responses and mRNA expression of tight junction genes in lambs fed a high-grain diet.
Controlled experiment in 16 lambs fed a high-grain diet Reading scope: PubMed bibliographic record and abstract |
VIP exposure altered selected inflammatory measures, but did not change the examined tight-junction gene expression. | The animal findings do not establish restoration of intestinal barrier function in people. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
A biomarker can rise as a compensatory response, reflect another process or simply correlate with disease. The direction of an association does not tell a reader what administering the molecule would do.
Keep null endpoints alongside positive ones. The lamb paper’s cytokine findings should not erase its lack of a demonstrated effect on the measured tight-junction transcripts.
Safety context
The selected observational human studies do not evaluate the safety of exogenous VIP. They cannot validate a nasal, injectable or other commercial regimen.
Study exposure and units
Separate blood concentrations used as biomarkers from an administered dose. Neither observational concentration nor a lamb exposure supplies a validated human treatment schedule.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Check the complete peptide identity and the actual formulation. A laboratory measurement of endogenous VIP in blood is not an assay of the contents of a commercial vial.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does a low VIP measurement prove that supplementation is needed?
No. The reviewed association studies do not establish a deficiency threshold, diagnostic rule or treatment decision.
Did the constipation paper test VIP?
The cited study tested a probiotic preparation and measured VIP among other changes. It cannot be presented as a trial of administered VIP.
Do the animal results prove a leaky-gut treatment?
No. The species, diet and endpoints differ, and the studied tight-junction gene measures did not show a treatment effect.
Sources
- Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. (PubMed bibliographic record and abstract)
- Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females. (PubMed bibliographic record and abstract)
- The impact of exogenous vasoactive intestinal polypeptide on inflammatory responses and mRNA expression of tight junction genes in lambs fed a high-grain diet. (PubMed bibliographic record and abstract)